New pathways on PharmGKB: Sorafenib PK and PD

We have added two new pathways: Sorafenib PK and PD pathways to our pathway collections.

Sorafenib (Nexavar, BAY 43-9006) is a cancer drug used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma.  It blocks tumor cell proliferation and angiogenesis by targeting various types of serine/threonine and receptor tyrosine kinases.  PharmGKB sorafenib PD pathway describes its mechanism of action and PK pathway depicts candidate genes mediating the metabolism, transport of sorafenib and possible drug-drug interactions.

View or download the pathways at Sorafenib PK and PD.

View all pathways at PharmGKB.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.